Geron Target of Unusually Large Options Trading (NASDAQ:GERN)

Geron Co. (NASDAQ:GERNGet Free Report) saw unusually large options trading on Friday. Stock investors bought 16,496 call options on the stock. This represents an increase of approximately 163% compared to the average daily volume of 6,265 call options.

Wall Street Analyst Weigh In

Several equities research analysts recently weighed in on the stock. TD Cowen started coverage on shares of Geron in a report on Monday, April 29th. They issued a “buy” rating and a $10.00 price objective for the company. Robert W. Baird cut shares of Geron from an “outperform” rating to a “neutral” rating and set a $4.50 price objective for the company. in a report on Tuesday, April 30th. The Goldman Sachs Group boosted their target price on Geron from $4.00 to $5.00 and gave the stock a “buy” rating in a report on Friday, March 15th. Wedbush reaffirmed an “outperform” rating and set a $7.00 price target on shares of Geron in a research note on Friday. Finally, Needham & Company LLC lifted their price target on Geron from $5.00 to $6.00 and gave the company a “buy” rating in a research report on Friday. One analyst has rated the stock with a hold rating and four have given a buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $6.50.

Get Our Latest Stock Analysis on GERN

Insider Transactions at Geron

In other Geron news, CEO John A. Scarlett sold 600,000 shares of the business’s stock in a transaction on Tuesday, June 4th. The shares were sold at an average price of $4.00, for a total transaction of $2,400,000.00. Following the completion of the sale, the chief executive officer now owns 600,000 shares in the company, valued at $2,400,000. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Insiders own 3.10% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the business. Rafferty Asset Management LLC boosted its holdings in Geron by 43.6% in the third quarter. Rafferty Asset Management LLC now owns 1,902,266 shares of the biopharmaceutical company’s stock valued at $4,033,000 after acquiring an additional 577,422 shares during the last quarter. BNP Paribas Financial Markets grew its position in shares of Geron by 37.9% during the 4th quarter. BNP Paribas Financial Markets now owns 714,012 shares of the biopharmaceutical company’s stock worth $1,507,000 after buying an additional 196,328 shares during the period. Wellington Management Group LLP raised its stake in shares of Geron by 3.4% during the third quarter. Wellington Management Group LLP now owns 10,405,626 shares of the biopharmaceutical company’s stock worth $22,060,000 after buying an additional 342,493 shares during the last quarter. Federated Hermes Inc. acquired a new position in Geron in the third quarter valued at approximately $29,000. Finally, Nan Fung Group Holdings Ltd boosted its stake in Geron by 94.2% in the third quarter. Nan Fung Group Holdings Ltd now owns 753,550 shares of the biopharmaceutical company’s stock valued at $1,598,000 after acquiring an additional 365,550 shares during the last quarter. 73.71% of the stock is owned by institutional investors and hedge funds.

Geron Stock Performance

Shares of NASDAQ GERN opened at $4.59 on Friday. The business’s 50-day simple moving average is $3.65 and its 200-day simple moving average is $2.69. The company has a debt-to-equity ratio of 0.03, a quick ratio of 3.67 and a current ratio of 3.67. Geron has a 52 week low of $1.64 and a 52 week high of $5.15. The firm has a market cap of $2.72 billion, a price-to-earnings ratio of -13.11 and a beta of 0.43.

Geron (NASDAQ:GERNGet Free Report) last issued its quarterly earnings results on Thursday, May 2nd. The biopharmaceutical company reported ($0.09) EPS for the quarter, topping the consensus estimate of ($0.10) by $0.01. Geron had a negative return on equity of 68.16% and a negative net margin of 38,730.00%. The company had revenue of $0.30 million for the quarter, compared to the consensus estimate of $0.15 million. As a group, equities research analysts expect that Geron will post -0.35 earnings per share for the current fiscal year.

About Geron

(Get Free Report)

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis.

Recommended Stories

Receive News & Ratings for Geron Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Geron and related companies with MarketBeat.com's FREE daily email newsletter.